TherapeuticsMD ( (TXMD) ) has released a notification of late filing.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
TherapeuticsMD, Inc. has filed a Form 12b-25 to notify investors of a brief delay in its Form 10-K (Yearly Report) for the financial year ended December 31, 2025. The company initially submitted its annual report on March 30, 2026, but that version was missing the audit report from its predecessor independent registered public accounting firm covering the 2024 financial statements.
Management explains that the omission stemmed from an inadvertent printer error rather than from accounting, internal control, or auditor disputes. Along with inserting the missing auditor report, the company used the extra time to fix several printer-related issues, including refreshing document hyperlinks to ensure the final filing is complete and accurate.
TherapeuticsMD states that the corrected Form 10-K (Yearly Report) was submitted with an official filing date of April 1, 2026. This timing falls within the 15-day grace period allowed under SEC Rule 12b-25 for late annual reports, meaning the company expects to remain in good standing with its periodic reporting obligations.
The company does not anticipate any significant change in its results of operations compared with the prior fiscal year as a result of this delay. Investors should note that any discussion of expected future filings and continued compliance is forward-looking in nature and inherently subject to risks and uncertainties.
TherapeuticsMD affirms that all other required periodic reports over the past 12 months have been filed on time. The notification is signed on behalf of the company by Chief Executive Officer Marlan D. Walker, signaling management’s commitment to maintaining timely disclosure and addressing the filing glitch promptly.
The most recent analyst rating on (TXMD) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on TherapeuticsMD stock, see the TXMD Stock Forecast page.
Spark’s Take on TXMD Stock
According to Spark, TipRanks’ AI Analyst, TXMD is a Neutral.
The score is held down primarily by weak financial fundamentals (notably the reported 2025 revenue collapse and ongoing losses), reinforced by bearish technical signals. Offsetting factors include improved cash generation and balance sheet leverage, plus a constructive corporate update showing narrowing losses and growing royalty/license revenue, but valuation support is limited at a ~20.6 P/E with no dividend.
To see Spark’s full report on TXMD stock, click here.
More about TherapeuticsMD
TherapeuticsMD, Inc. is a healthcare company based in Boca Raton, Florida. It focuses on developing and commercializing products in the therapeutic space, with its securities registered under the Securities Exchange Act of 1934.
Average Trading Volume: 76,082
Technical Sentiment Signal: Hold
Current Market Cap: $23.38M
Learn more about TXMD stock on TipRanks’ Stock Analysis page.